Full Press Release Details
| Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) | |||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | ||||||
| Total Revenues | $ 595.3 | $ 533.8 | 12 % | $ 1,191.7 | $ 1,053.2 | 13 % | |||||
| Total Enzyme Product Revenues (1) | $ 420.8 | $ 425.7 | (1) % | $ 868.8 | $ 852.3 | 2 % | |||||
| VIMIZIM ® Net Product Revenues | $ 177.4 | $ 173.3 | 2 % | $ 366.6 | $ 356.4 | 3 % | |||||
| VOXZOGO ® Net Product Revenues | $ 113.3 | $ 34.4 | 229 % | $ 201.2 | $ 54.0 | 273 % | |||||
| NAGLAZYME ® Net Product Revenues | $ 90.1 | $ 115.8 | (22) % | $ 213.1 | $ 243.8 | (13) % | |||||
| PALYNZIQ ® Net Product Revenues | $ 74.9 | $ 61.6 | 22 % | $ 137.2 | $ 116.5 | 18 % | |||||
| KUVAN ® Net Product Revenues | $ 50.6 | $ 57.6 | (12) % | $ 101.1 | $ 116.9 | (14) % | |||||
| ALDURAZYME ® Net Product Revenues | $ 40.3 | $ 37.3 | 8 % | $ 74.7 | $ 61.7 | 21 % | |||||
| BRINEURA ® Net Product Revenues | $ 38.1 | $ 37.7 | 1 % | $ 77.2 | $ 73.9 | 4 % | |||||
| GAAP Net Income (2) | $ 56.0 | $ 27.7 | $ 106.9 | $ 148.5 | |||||||
| Non-GAAP Income (3) | $ 105.2 | $ 76.8 | $ 221.0 | $ 175.7 | |||||||
| GAAP Diluted Earnings per Share (EPS) | $ 0.29 | $ 0.15 | $ 0.56 | $ 0.79 | |||||||
| Non-GAAP Diluted EPS (4) | $ 0.54 | $ 0.41 | $ 1.14 | $ 0.93 |
| June 30, 2023 | December 31, 2022 | ||
| Total cash, cash equivalents & investments | $ 1,556.7 | $ 1,625.4 |
| (1) | Enzyme-based products include ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ, and VIMIZIM. |
| (2) | GAAP Net income in the first half of 2022 included a $89.0 million gain, net of taxes, related to the sale of the Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the U.S. Food and Drug Administration (FDA) in connection with U.S. approval of VOXZOGO. |
| (3) | Non-GAAP Income is defined by the Company as reported GAAP Net Income, excluding amortization expense, stock-based compensation expense, contingent consideration, and, in certain periods, certain other specified items. The Company also includes a Non-GAAP adjustment for the estimated income tax impact of reconciling items. Refer to Non-GAAP Information beginning on page 9 of this press release for a complete discussion of the Company's Non-GAAP financial information and reconciliations to the comparable information reported under U.S. GAAP. |
| (4) | Non-GAAP Diluted EPS is defined by the Company as Non-GAAP Income divided by Non-GAAP diluted shares outstanding. |
SAN RAFAEL, Calif. , July 31, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced financial results for the six months and second quarter ended June 30, 2023.
"Outstanding execution across our business led to record revenues in the first half of 2023. We reached more children with VOXZOGO around the world, as physicians and families sought treatment with the only approved medicine targeting the genetic cause of achondroplasia," said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin. "We were also very pleased to have received the highly anticipated U.S. approval of ROCTAVIAN, the only gene therapy treatment for severe hemophilia A. U.S. commercial launch activities are well underway following the June 29 approval, in parallel with launch progress across a number of European countries."
BioMarin Announces Record Breaking Revenues for the First Half of 2023
Mr. Bienaimé added, "for the remainder of 2023, we plan to build on the foundation of growth and profitability achieved in the first half of the year, expand VOXZOGO globally and treat the first ROCTAVIAN patients in the U.S. and Europe ."
Financial Highlights:
Recent Product Approvals and Launches (ROCTAVIAN and VOXZOGO)
VOXZOGO and ROCTAVIAN Market Expansion Opportunities
Earlier-stage Development Portfolio (BMN 255, BMN 331, BMN 351, BMN 349, BMN 293)
2023 Full-Year Financial Guidance (in millions, except % and EPS amounts) (Updated)
| Item | 2023 Guidance | Updated July 31, 2023 | ||||||||||
| Total Revenues | $2,375 | to | $2,500 | Unchanged | ||||||||
| Enzyme Product Revenues (1) | $1,700 | to | $1,850 | Unchanged | ||||||||
| ROCTAVIAN Revenues | $50 | to | $150 | Unchanged | ||||||||
| VOXZOGO Revenues | $380 | to | $430 | $400 | to | $440 | ||||||
| Unchanged | ||||||||||||
| Gross Profit % | 77.5 % | to | 79 % | Unchanged | ||||||||
| R&D % of Revenue | 30 % | to | 32 % | Unchanged | ||||||||
| SG&A % of Revenue | 36 % | to | 38 % | 35.5 % | to | 37.5 % | ||||||
| GAAP Net Income | $155 | to | $205 | $165 | to | $215 | ||||||
| GAAP Diluted EPS | $0.78 | to | $1.03 | $0.83 | to | $1.08 | ||||||
| Non-GAAP Income | $360 | to | $410 | $370 | to | $420 | ||||||
| Non-GAAP Diluted EPS | $1.80 | to | $2.05 | $1.85 | to | $2.10 |
BioMarin will host a conference call and webcast to discuss second quarter 2023 financial results today, Monday, July 31, 2023, at 4:30 p.m. ET . This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com.
| U.S./Canada Dial-in Number: 888-886-7786 | Replay Dial-in Number: 877-674-7070 |
| International Dial-in Number: 416-764-8658 | Replay International Dial-in Number: 416-764-8692 |
| No Conference ID: 93773398 | Conference ID: 773398 # |
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin's robust research and development capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com .
Forward-Looking Statements
BioMarin ® , BRINEURA ® , KUVAN ® , NAGLAZYME ® , PALYNZIQ ® , VIMIZIM ® and VOXZOGO ® are registered trademarks of BioMarin Pharmaceutical Inc., or its affiliates. ROCTAVIAN TM is a trademark of BioMarin Pharmaceutical Inc. ALDURAZYME ® is a registered trademark of BioMarin/Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this release are the property of their respective owners.
| BIOMARIN PHARMACEUTICAL INC. | |||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||
| June 30, 2023 and December 31, 2022 | |||
| (In thousands of U.S. dollars, except per share amounts) | |||
| June 30, 2023 | December 31, 2022 ⁽¹⁾ | ||
| ASSETS | (unaudited) | ||
| Current assets: | |||
| Cash and cash equivalents | $ 694,381 | $ 724,531 | |
| Short-term investments | 476,577 | 567,006 | |
| Accounts receivable, net | 610,222 | 461,316 | |
| Inventory | 975,546 | 894,083 | |
| Other current assets | 193,391 | 104,521 | |
| Total current assets | 2,950,117 | 2,751,457 | |
| Noncurrent assets: | |||
| Long-term investments | 385,777 | 333,835 | |
| Property, plant and equipment, net | 1,067,278 | 1,073,366 | |
| Intangible assets, net | 310,343 | 338,569 | |
| Goodwill | 196,199 | 196,199 | |
| Deferred tax assets | 1,509,290 | 1,505,412 | |
| Other assets | 144,168 | 176,236 | |
| Total assets | $ 6,563,172 | $ 6,375,074 | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||
| Current liabilities: | |||
| Accounts payable and accrued liabilities | $ 597,231 | $ 572,959 | |
| Short-term contingent consideration | — | 15,925 | |
| Total current liabilities | 597,231 | 588,884 | |
| Noncurrent liabilities: | |||
| Long-term convertible debt, net | 1,084,994 | 1,083,019 | |
| Other long-term liabilities | 98,120 | 100,015 | |
| Total liabilities | 1,780,345 | 1,771,918 | |
| Stockholders' equity: | |||
| Common stock, $0.001 par value: 500,000,000 shares authorized; 188,151,695 and 186,250,719 shares issued and outstanding, respectively | 188 | 186 | |
| Additional paid-in capital | 5,493,956 | 5,404,895 | |
| Company common stock held by the Nonqualified Deferred Compensation Plan | (10,393) | (8,859) | |
| Accumulated other comprehensive loss | (18,617) | (3,867) | |
| Accumulated deficit | (682,307) | (789,199) | |
| Total stockholders' equity | 4,782,827 | 4,603,156 | |
| Total liabilities and stockholders' equity | $ 6,563,172 | $ 6,375,074 |
| BIOMARIN PHARMACEUTICAL INC. | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
| Three and Six Months Ended June 30, 2023 and 2022 | |||||||
| (In thousands of U.S. dollars, except per share amounts) | |||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||
| 2023 | 2022 | 2023 | 2022 | ||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | ||||
| REVENUES: | |||||||
| Net product revenues | $ 584,698 | $ 517,660 | $ 1,171,124 | $ 1,023,185 | |||
| Royalty and other revenues | 10,577 | 16,138 | 20,566 | 29,972 | |||
| Total revenues | 595,275 | 533,798 | 1,191,690 | 1,053,157 | |||
| OPERATING EXPENSES: | |||||||
| Cost of sales | 128,082 | 123,126 | 254,631 | 240,091 | |||
| Research and development | 177,363 | 158,190 | 349,209 | 319,026 | |||
| Selling, general and administrative | 215,336 | 196,835 | 438,339 | 391,454 | |||
| Intangible asset amortization and contingent consideration | 15,624 | 16,495 | 31,294 | 34,107 | |||
| Gain on sale of nonfinancial assets, net | — | — | — | (108,000) | |||
| Total operating expenses | 536,405 | 494,646 | 1,073,473 | 876,678 | |||
| INCOME FROM OPERATIONS | 58,870 | 39,152 | 118,217 | 176,479 | |||
| Interest income | 12,612 | 2,505 | 24,555 | 4,325 | |||
| Interest expense | (3,755) | (3,859) | (7,458) | (7,665) | |||
| Other income (expense), net | 3,083 | (2,947) | (7,747) | (4,101) | |||
| INCOME BEFORE INCOME TAXES | 70,810 | 34,851 | 127,567 | 169,038 | |||
| Provision for income taxes | 14,770 | 7,187 | 20,675 | 20,576 | |||
| NET INCOME | $ 56,040 | $ 27,664 | $ 106,892 | $ 148,462 | |||
| EARNINGS PER SHARE, BASIC | $ 0.30 | $ 0.15 | $ 0.57 | $ 0.80 | |||
| EARNINGS PER SHARE, DILUTED | $ 0.29 | $ 0.15 | $ 0.56 | $ 0.79 | |||
| Weighted average common shares outstanding, basic | 187,948 | 185,254 | 187,311 | 184,710 | |||
| Weighted average common shares outstanding, diluted | 194,998 | 187,448 | 194,756 | 191,096 |
| BIOMARIN PHARMACEUTICAL INC. | |||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
| Six Months Ended June 30, 2023 and 2022 | |||
| (In thousands of U.S. dollars) | |||
| Six Months Ended June 30, | |||
| 2023 | 2022 | ||
| (unaudited) | (unaudited) | ||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||
| Net income | $ 106,892 | $ 148,462 | |
| Adjustments to reconcile net income to net cash used in operating activities: | |||
| Depreciation and amortization | 51,840 | 52,614 | |
| Non-cash interest expense | 2,058 | 2,062 | |
| Amortization of premium (accretion of discount) on investments | (4,533) | 3,070 | |
| Stock-based compensation | 103,857 | 94,911 | |
| Gain on sale of nonfinancial assets, net | — | (108,000) | |
| Loss on equity investment | 12,650 | — | |
| Deferred income taxes | (5,108) | 3,455 | |
| Unrealized foreign exchange loss (gain) | 7,455 | (12,333) | |
| Non-cash changes in the fair value of contingent consideration | — | 1,338 | |
| Other | 361 | (18) | |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (145,831) | (92,562) | |
| Inventory | (56,476) | (1,431) | |
| Other current assets | (53,430) | (12,001) | |
| Other assets | (5,616) | 9,149 | |
| Accounts payable and other short-term liabilities | (25,093) | (76,345) | |
| Other long-term liabilities | 7,104 | (1,576) | |
| Net cash provided by (used in) operating activities | (3,870) | 10,795 | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||
| Purchases of property, plant and equipment | (46,039) | (55,971) | |
| Maturities and sales of investments | 491,063 | 311,598 | |
| Purchases of investments | (444,049) | (304,805) | |
| Proceeds from sale of nonfinancial assets | — | 110,000 | |
| Purchase of intangible assets | (1,457) | (2,739) | |
| Net cash provided by (used in) investing activities | (482) | 58,083 | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||
| Proceeds from exercises of awards under equity incentive plans | 50,193 | 29,493 | |
| Taxes paid related to net share settlement of equity awards | (67,862) | (44,377) | |
| Payments of contingent consideration | (9,475) | (21,054) | |
| Principal repayments of financing leases | (1,635) | (1,122) | |
| Net cash used in financing activities | (28,779) | (37,060) | |
| Effect of exchange rate changes on cash | 2,981 | 708 | |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (30,150) | 32,526 | |
| Cash and cash equivalents: | |||
| Beginning of period | $ 724,531 | $ 587,276 | |
| End of period | $ 694,381 | $ 619,802 |
Non-GAAP Information
The results presented in this press release include both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the Company as GAAP Net Income excluding amortization expense, stock-based compensation expense, contingent consideration expense, and, in certain periods, certain other specified items, as detailed below when applicable. The Company also includes a Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP Diluted EPS is defined by the Company as Non-GAAP Income divided by Non-GAAP diluted shares outstanding
Non-GAAP Income and its components are not meant to be considered in isolation or as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its Non-GAAP financial measures; likewise, the Company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. Because of the non-standardized definitions, the Non-GAAP financial measure as used by BioMarin in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
The following tables present the reconciliation of GAAP reported to Non-GAAP adjusted financial information:
| Reconciliation of GAAP Reported Net Income to Non-GAAP Income (1) | |||||||
| (In millions of U.S. dollars) | |||||||
| (unaudited) | |||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||
| 2023 | 2022 | 2023 | 2022 | ||||
| GAAP Reported Net Income | $ 56.0 | $ 27.7 | $ 106.9 | $ 148.5 | |||
| Adjustments | |||||||
| Stock-based compensation expense - COS | 4.7 | 4.8 | 9.1 | 9.1 | |||
| Stock-based compensation expense - R&D | 15.1 | 13.6 | 34.9 | 30.8 | |||
| Stock-based compensation expense - SG&A | 30.4 | 28.7 | 59.9 | 55.0 | |||
| Amortization of intangible assets | 15.6 | 15.6 | 31.3 | 31.2 | |||
| Contingent consideration | — | 0.9 | — | 2.9 | |||
| Gain on sale of non-financial assets (2) | — | — | — | (108.0) | |||
| Severance and employee termination benefits (3) | (2.2) | — | (0.1) | — | |||
| Loss on investment in equity securities (4) | — | — | 12.6 | — | |||
| Income tax effect of adjustments | (14.4) | (14.5) | (33.6) | 6.2 | |||
| Non-GAAP Income | $ 105.2 | $ 76.8 | $ 221.0 | $ 175.7 |
| Reconciliation of Certain GAAP Reported Information to Non-GAAP Information | |||||||
| (in millions, except per share data) | |||||||
| (unaudited) | |||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||
| 2023 | 2022 | 2023 | 2022 | ||||
| GAAP Diluted EPS | $ 0.29 | $ 0.15 | $ 0.56 | $ 0.79 | |||
| Adjustments | |||||||
| Stock-based compensation expense | 0.25 | 0.25 | 0.52 | 0.49 | |||
| Amortization of intangible assets | 0.08 | 0.08 | 0.16 | 0.16 | |||
| Contingent consideration | — | — | — | 0.01 | |||
| Gain on sale of non-financial assets (2) | — | — | — | (0.55) | |||
| Severance and employee termination benefits (3) | (0.01) | — | — | — | |||
| Loss on investment in equity securities (4) | — | — | 0.06 | — | |||
| Income tax effect of adjustments | (0.07) | (0.08) | (0.16) | 0.03 | |||
| Non-GAAP Diluted EPS | $ 0.54 | $ 0.41 | $ 1.14 | $ 0.93 |
| (1) | Certain amounts may not sum or recalculate due to rounding. |
| (2) | Represents the net gain in the first quarter of 2022 on the sale to a third party of the PRV the Company received from the FDA in connection with the U.S. approval of VOXZOGO. |
| (3) | Represents change in estimates to severance and employee termination benefit charges in SG&A related to the Company's organizational redesign announced in October 2022. The Company recognized $23.0 million of expense related to severance and employee termination benefits in the second half of 2022. |
| (4) | Represents the impairment loss on investment in non-marketable equity securities recorded in Other income (expense), net in the first quarter of 2023. |
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||
| 2023 | 2022 | 2023 | 2022 | ||||
| GAAP Weighted-Average Dilutive Shares Outstanding | 195.0 | 187.4 | 194.8 | 191.1 | |||
| Adjustments | |||||||
| Common stock issuable under Company's convertible debt (1) | 4.4 | 4.0 | 4.4 | 4.4 | |||
| Non-GAAP Weighted-Average Dilutive Shares Outstanding | 199.4 | 191.4 | 199.2 | 195.5 |
| Guidance for the Year Ended December 31, 2023 (1)(2) | ||||||||||
| Net Income | Diluted Shares | Diluted EPS | ||||||||
| GAAP Net Income and Diluted EPS | $ 165 | to | $ 215 | 200 | $0.83 | to | $1.08 | |||
| Amortization of intangible assets | 60 | 0.30 | ||||||||
| Stock-based compensation expense | 200 | 1.00 | ||||||||
| Severance and employee termination benefits | (0.1) | — | ||||||||
| Loss on investment in equity securities | 12.6 | 0.06 | ||||||||
| Income tax effect of adjustments (3) | (68) | (0.34) | ||||||||
| Non-GAAP Income and Diluted EPS | $ 370 | to | $ 420 | 200 | $1.85 | to | $2.10 |
| (1) | The adjustments/reconciling items included in this table are presented to facilitate the reconciliation of Non-GAAP Income and Non- GAAP Diluted EPS to their closest GAAP financial metrics, GAAP Net Income and GAAP Diluted EPS. The specific amounts included in each reconciling line item above represent approximations of the underlying adjustments from GAAP Net Income to Non-GAAP Income and from GAAP Diluted EPS to Non-GAAP Diluted EPS. Actual 2023 results for each reconciling line item may be different, in some cases materially, than the amounts listed above as a result of uncertainty regarding, and the potential variability of, those items. |
| (2) | Certain amounts may not sum or recalculate due to rounding. |
| (3) | Income tax adjustments represent the estimated income tax impact of each pre-tax non-GAAP adjustment based on the applicable statutory income tax rate. |
| Contact: | ||
| Investors: | Media: | |
| Traci McCarty | Marni Kottle | |
| BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. | |
| (415) 455-7558 | (650) 374-2803 |
SOURCE BioMarin Pharmaceutical Inc.